130 related articles for article (PubMed ID: 35151817)
1. Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ
Sweeney C; Dudhipala N; Thakkar R; Mehraj T; Marathe S; Gul W; ElSohly MA; Murphy B; Majumdar S
Int J Pharm; 2022 Mar; 616():121564. PubMed ID: 35151817
[TBL] [Abstract][Full Text] [Related]
2. Effect of surfactant concentration and sterilization process on intraocular pressure-lowering activity of Δ
Sweeney C; Dudhipala N; Thakkar R; Mehraj T; Marathe S; Gul W; ElSohly MA; Murphy B; Majumdar S
Drug Deliv Transl Res; 2021 Oct; 11(5):2096-2107. PubMed ID: 33169348
[TBL] [Abstract][Full Text] [Related]
3. Δ
Taskar PS; Patil A; Lakhani P; Ashour E; Gul W; ElSohly MA; Murphy B; Majumdar S
Transl Vis Sci Technol; 2019 Sep; 8(5):15. PubMed ID: 31588378
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure in Normotensive Dutch-Belted Rabbits.
Senapati S; Youssef AAA; Sweeney C; Cai C; Dudhipala N; Majumdar S
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559077
[TBL] [Abstract][Full Text] [Related]
5. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
Adelli GR; Bhagav P; Taskar P; Hingorani T; Pettaway S; Gul W; ElSohly MA; Repka MA; Majumdar S
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2167-2179. PubMed ID: 28399267
[TBL] [Abstract][Full Text] [Related]
6. Formulation and In Vitro-Ex vivo Evaluation of Cannabidiol and Cannabidiol-Valine-Hemisuccinate Loaded Lipid-Based Nanoformulations for Ocular Applications.
Adel Ali Youssef A; Hayder Abdelrahman M; Geweda MM; Varner C; Joshi PH; Ghonge M; Dudhipala N; Sulochana SP; Gadepalli RS; Majumdar S
Int J Pharm; 2024 May; 657():124110. PubMed ID: 38604539
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles.
Halder A; Khopade AJ
Curr Eye Res; 2021 Jul; 46(7):1031-1037. PubMed ID: 33719796
[No Abstract] [Full Text] [Related]
8. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits.
Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A
J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071
[TBL] [Abstract][Full Text] [Related]
9. Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits.
Rubenicia AML; Cubillan LDP; Sicam VADP; Macabeo APG; Villaflores OB; Castillo AL
Transl Vis Sci Technol; 2021 Apr; 10(4):2. PubMed ID: 34003979
[TBL] [Abstract][Full Text] [Related]
10. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits.
Muchtar S; Almog S; Torracca MT; Saettone MF; Benita S
Ophthalmic Res; 1992; 24(3):142-9. PubMed ID: 1328979
[TBL] [Abstract][Full Text] [Related]
11. Interaction between delta-9-tetrahydrocannabinol and indomethacin.
Green K; Kearse EC; McIntyre OL
Ophthalmic Res; 2001; 33(4):217-20. PubMed ID: 11464074
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
[TBL] [Abstract][Full Text] [Related]
13. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
[TBL] [Abstract][Full Text] [Related]
16. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
Gelatt KN; MacKay EO
Vet Ophthalmol; 2001 Dec; 4(4):283-8. PubMed ID: 11906665
[TBL] [Abstract][Full Text] [Related]
17. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
Aref AA; Geyman LS; Zakieh AR; Alotaibi HM
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1073-1079. PubMed ID: 31842637
[No Abstract] [Full Text] [Related]
18. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma.
Crandall J; Matragoon S; Khalifa YM; Borlongan C; Tsai NT; Caldwell RB; Liou GI
Ophthalmic Res; 2007; 39(2):69-75. PubMed ID: 17284931
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
